RDHL - RedHill Biopharma Ltd.
| Previous Close | 4.9200 |
| Open | 4.9400 |
| Bid | 4.7700 x 1200 |
| Ask | 5.2200 x 1400 |
| Day's Range | 4.9300 - 5.0500 |
| 52 Week Range | 4.8600 - 9.2000 |
| Volume | 137,063 |
| Avg. Volume | 207,973 |
| Market Cap | 240.148M |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- American City Business Journals
RedHill Biopharma shifts course to put more focus on lead drug candidates
RedHill Biopharma will end its commercialization agreements with Entera Health and Advanz Pharma Corp.
- Zacks
Zacks Market Edge Highlights: Boot Barn, Alteryx, RedHill Biopharma, Innovative Industrial Properties and SPS Commerce
Zacks Market Edge Highlights: Boot Barn, Alteryx, RedHill Biopharma, Innovative Industrial Properties and SPS Commerce
- Zacks
How to Screen for the Best Growth Stocks
Wouldn't you like a list of the top growth stocks right now?
- Zacks
Rigel Gets Positive CHMP Review for Thrombocytopenia Drug
The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.
- American City Business Journals
Triangle company builds workforce as it preps for commercialization
A Triangle company's long-anticipated FDA approval has arrived, meaning the company is poised to start commercialization efforts it hopes will net a profit.
- Reuters
UPDATE 2-U.S. FDA approves RedHill's bacterial infection treatment
RedHill Biopharma Ltd's said on Monday its three-drug combination therapy to treat Helicobacter pylori bacterial infections had been approved by the U.S. Food and Drug Administration, sending its shares up 25%. The drug, Talicia, is an oral capsule comprising two antibiotics, amoxicillin and rifabutin, as well as omeprazole, a common treatment for heartburn. The Israel-based company said the drug was designed to address the high resistance of H. pylori bacteria to current clarithromycin-based standard-of-care therapies.
- Reuters
U.S. FDA approves RedHill's H. pylori infection treatment
The U.S. Food and Drug Administration has approved RedHill Biopharma Ltd's drug to treat infections caused by bacteria known as Helicobacter pylori, the Israel-based company said on Monday. RedHill expects to launch the drug, Talicia, in the United States in the first quarter next year. Helicobacter pylori infection affects over 50% of the population worldwide, according to Redhill, and is one of the strongest risk factor for the development of gastric cancer.
- Benzinga
Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
The FDA worked overtime in October , deciding on the fate of several therapies and treatment options. Most reviews produced positive outcomes. Three new molecular entities, or NMEs, were approved in October, ...
- Benzinga
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Earnings, clinical trial readouts and positive FDA verdicts catalyzed fairly robust performances by biotech stocks last week. Biogen Inc (NASDAQ: BIIB )'s about-face with respect to its Alzheimer's drug ...
- American City Business Journals
Triangle drugmaker lands $36M deal with Ireland-based pharma
On the eve of a Triangle drugmaker's approval for its lead candidate, it has struck a deal with a major pharmaceutical company for $36 million and rights to a new drug – selling off about 20 percent of its stock in the deal.
- TheStreet.com
3 Small-Caps That Look Like Bargains at Current Trading Levels
No resolution seems on the horizon on the U.S.-China trade front as both sides have dug in their heels. Since the end of February the S&P 500 has continued to advance despite a pullback in May, while the Russell 2000 has stalled out. Let's look at three small-caps that seem like good bargains at current trading levels, starting with BioDelivery Sciences International Inc. .
- Motley Fool
3 Biotech Stocks That Could Double Your Money
Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.
